DOCSLIB.ORG

Opioid-Cannabinoid Codrugs with Enhanced Analgesic and Pharmacokinetic Profile

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioid-Cannabinoid Codrugs with Enhanced Analgesic and Pharmacokinetic Profile University of Kentucky UKnowledge University of Kentucky Doctoral Dissertations Graduate School 2010 OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE Harpreet Kaur Dhooper University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Dhooper, Harpreet Kaur, "OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE" (2010). University of Kentucky Doctoral Dissertations. 98. https://uknowledge.uky.edu/gradschool_diss/98 This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of UKnowledge. For more information, please contact [email protected]. ABSTRACT OF DISSERTATION Harpreet Kaur Dhooper College of Arts & Sciences University of Kentucky 2010 OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE _________________________________________ ABSTRACT OF DISSERTATION _________________________________________ A dissertation submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy in the College of Arts & Sciences at the University of Kentucky By Harpreet Kaur Dhooper Lexington, Kentucky Director: Dr. Peter A. Crooks, Professor of Pharmaceutical Sciences Lexington, Kentucky 2010 Copyright © Harpreet Dhooper 2010 ABSTRACT OF DISSERTATION OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE The central hypothesis of the dissertation is that “the design and synthesis of a codrug of an opiate and a cannabinoid can be achieved which is stable in the gastrointestinal tract and shows a superior pharmacological and pharmacokinetic profile when compared to a physical mixture of the two parent drugs.” To prove the hypothesis, a series of novel codrugs were prepared by conjugation of the opiate drug codeine with ∆9- tetrahydrocannabinol (∆9-THC), cannabidiol, abn-cannabidiol and an opiate prodrug 3-O- acetylmorphine with ∆9-THC. Codeine-cannabinoid codrugs were evaluated for analgesic activity in the rat after oral administration. The Cod-THC codrug showed greater effectiveness as well as prolonged pain management properties as compared to the parent drugs. The stability of Cod-THC codrug in aqueous solutions from pH 1-9, in simulated gastrointestinal fluids, in brain homogenate and the hydrolysis of the carbonate ester linkage in rat plasma suggested that after oral administration, the codrug would be absorbed intact from the GI tract and then hydrolyze in the plasma to generate both parent drugs. The enzymes present in rat brain homogenate were incapable of cleaving the codrug into the parent drugs. The pharmacokinetic profiles of the Cod-THC codrug and an equimolar physical mixture of the parent drugs were evaluated in rats. The plasma concentrations of codeine and∆ 9- THC were much higher after codrug administration compared to the plasma concentrations of these drugs after oral administration of an equimolar physical mixture. The parent drugs were also present in the plasma for longer period of time compared to the physical mixture, probably due to the sustained release of the parent drugs from codrug in the plasma. The concentrations of codeine and Δ9-THC were much higher in rat brain after oral administration of the Cod-THC codrug as compared to brain concentrations of these drugs after oral administration of the physical mixture. Thus, the design and synthesis of an opiate and a cannabinoid codrug was achieved which was stable in the gastrointestinal tract, showed enhanced analgesic effects as compared to the parent drugs, and also showed a superior pharmacokinetic profile when compared to a physical mixture or the two parent drugs. KEYWORDS: Opioid, Cannabinoid, Codrug, Antinociception, Pharmacokinetics Harpreet Dhooper Date OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE By Harpreet Kaur Dhooper ____________________________________ Director of Dissertation ____________________________________ Director of Graduate Studies ____________________________________ Date RULES FOR THE USE OF DISSERTATIONS Unpublished dissertation submitted for the Doctor’s degree and deposited in the University of Kentucky Library are as a rule open for inspection, but are to be used only with due regard to the rights of the authors. Bibliographical references may be noted, but quotations and summaries of parts may be published only with the permission of the author, and with the usual scholarly acknowledgement. Extensive copying or publication of the dissertation in whole or in part also requires the consent of the Dean of the Graduate School of the University of Kentucky. A library that borrows this dissertation for use by its patrons is expected to secure the signature of each user. Name Date ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ DISSERTATION Harpreet Kaur Dhooper College of Arts and Sciences University of Kentucky 2010 OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND PHARMACOKINETIC PROFILE ________________________________________ DISSERTATION ________________________________________ A dissertation submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy in the College of Arts & Sciences at the University of Kentucky By Harpreet Kaur Dhooper Lexington, Kentucky Director: Dr. Peter A. Crooks, Professor of Pharmaceutical Sciences Lexington, Kentucky 2010 Dedication To my parents ACKNOWLEDGEMENTS Foremost, I would like to express my sincere gratitude to my advisor Dr. Peter A. Crooks for the continuous support of my Ph.D study and research, for his patience, motivation, enthusiasm, and immense knowledge. His guidance helped me in all the time of research and writing of this thesis. I could not have imagined having a better advisor and mentor for my Ph.D study. I would like to thank all my advisory committee members, Dr. Stephen Testa, Dr. Abeer Al-Ghananeem, Dr. Joseph Holtman, Dr. Boyd Haley and Dr. Mark Watson for their time, and suggestions in designing some of the experiments. I am grateful to Dr. Zaineb Albayati and Dr. Elzbeita Wala for helping me with all the animal work. I thank Dr. Malkawi for his help with the HPLC studies of the drugs. I would like to thank Dr. Jamie Horn and John May for their help with the LC-MS/MS studies. I am thankful to Dr. Peter Wedlund for helping me with pharmacokinetics. I would also like to thank my friend, Ujjwal Chakraborty for his constant support. He has always been a constant source of encouragement during my graduate study. Additionally, I am very grateful for the friendship of all of the members of Crooks’ research group with whom I worked closely and puzzled over many problems. I want to thank my father-in-law Dr. Surjit Singh Dhooper without whom I would never have been able to achieve so much. He has always been one of my best counselors. I also want to thank my mother-in-law, my husband and my kids, Mantegh and Sachleen for their moral suppo rt. I am extremely thankful to my parents, the reason for my existence. I would like to dedicate this dissertation research to them. Without their sacrifice, blessings and encouragement it would have been impossible to reach this stage. I have no suitable words that can fully describe their everlasting love to me. Although they are no longer with me, they are forever remembered. I am sure they share our joy and happiness in the heaven. The support of my brother and sisters is also greatly appreciated. III TABLE OF CONTENTS Acknowledgements III List of Figures VIII List of Schemes XIV List of Tables XVI Chapter 1. Objects of the Study and Literature Review 1.1 Hypothesis 1 1.2 Overall Aim 1 1.3 Methodology to be utilized in this study 2 1.4 Literature Review 1.4.1 Codrugs/Hybrid Drugs 3 1.4.2 Marketed Codrug 9 1.4.3 Codrug for the Treatment of Proliferative Diabetic Retinopathy 10 1.4.4 Codrug for the Simultaneous Treatment of Alcohol Abuse and Tobacco Dependence 15 1.4.5 L-DOPA Codrugs 23 1.5 Codrug strategy in pain management 1.5.1 Opioids and Cannabinoids 28 1.5.2 Pharmacokinetics and Pharmacodynamics of Opioids 28 1.5.3 Pharmacokinetics and Pharmacodynamics of Cannabinoids 31 Chapter 2. Synthesis of Codrugs and Parent drugs 2.1 Synthesis of ∆9-Tetrahydrocannabinol (∆ 9-THC) 35 2.2 Synthesis of (-)-Cannabidiol (CBD) 36 2.3 Codeine-∆9-Tetrahydrocannabinol (Cod-THC) Codrug Synthesis 47 2.4 Synthesis of the Codeine-(-)-Cannabidiol (Cod-CBD) 60 IV 2.5 Synthesis of the Codeine-abnCannabidiol (Cod-abnCBD) 61 2.6 Synthesis of the 3-O-acetylmorphine-∆9-tetrahydrocannabinol (AcMor-THC) 63 2.7 Experimental Section 7 Chapter 3. The Analgesic activities of Codrugs and
Load more

Recommended publications
  • 2019 Ministerial Declaration
    COMMISSION ON NARCOTIC DRUGS VIENNA IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Commission on Narcotic Drugs IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS Vienna, 2019 © United Nations, July 2019. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Contents 1. Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem ...............................1 2. Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” ..................................................9 3. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem ...............................35 4.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • Synthetic Drugs: Overview and Issues for Congress
    Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013.
    [Show full text]
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]
  • Exposures Associated with Clandestine Methamphetamine Drug Laboratories in Australia
    Rev Environ Health 2016; 31(3): 329–352 Jackie Wright*, John Edwards and Stewart Walker Exposures associated with clandestine methamphetamine drug laboratories in Australia DOI 10.1515/reveh-2016-0017 Received April 20, 2016; accepted June 7, 2016; previously published Introduction online July 18, 2016 Illicit drugs such as amphetamine-type stimulants (ATS) Abstract: The clandestine manufacture of methamphet- (1) are manufactured in Australia within clandestine amine in residential homes may represent significant laboratories that range from crude, makeshift operations hazards and exposures not only to those involved in the using simple processes to sophisticated operations. These manufacture of the drugs but also to others living in the laboratories use a range of chemical precursors to manu- home (including children), neighbours and first respond- facture or “cook” ATS that include methylamphetamine, ers to the premises. These hazards are associated with more commonly referred to as methamphetamine (“ice”) the nature and improper storage and use of precursor and 3,4-methylenedioxymethamphetamine (MDMA or chemicals, intermediate chemicals and wastes, gases and “ecstasy”). In Australia the primary ATS manufactured methamphetamine residues generated during manufac- in clandestine drug laboratories is methamphetamine ture and the drugs themselves. Many of these compounds (2), which is the primary focus of this review. Clandes- are persistent and result in exposures inside a home not tine laboratories are commonly located within residential only during manufacture but after the laboratory has been homes, units, hotel rooms, backyard sheds and cars, with seized or removed. Hence new occupants of buildings for- increasing numbers detected in Australia each year (744 merly used to manufacture methamphetamine may be laboratories detected in 2013–2014) (2).
    [Show full text]
  • Nitrosamines EMEA-H-A5(3)-1490
    25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines
    [Show full text]
  • Non-Alcohol Sedative Hypnotics
    Tom Fowlkes, MD Director of Professional & Medical Relations American Addiction Centers Oxford Treatment Center More Accurately We Will Talk About: Non-alcohol Sedative Hypnotics Objectives To review the history & pharmacology of benzodiazepines and other sedative-hypnotics To educate prescribers about the indications for the proper use of benzodiazepines To educate prescribers about the indications for discontinuation of therapy and tapering strategies To review recent information about benzodiazepine use and abuse Disclosures I have nothing to disclose. Except perhaps that I make my living treating people with substance abuse disorders and as a result I have not become the biggest advocate for widespread benzodiazepine use. Most of the information in this talk is taken from the medical literature. Some of the information is my own medical opinion. I have tried to point out when information is my opinion. What we are going to cover 2 Case studies What are Sedative Hypnotics/How they work History – Older Sedative-Hypnotics>BZ>Newer Drugs Pharmacology Differences in benzodiazepines (=benzo’s, = BZ) Clinical Use Safe Prescribing Abuse & Dependence Sedative-Hypnotics Suppress CNS activity Pharmacologically diverse Cause effects along a continuum of: calming> sleep >unconsciousness > coma > death Uses: Anxiolytics Hypnotics Anti-convulsants Muscle relaxants Anesthesia induction (Olkkola, 2008) GABA System Most all of these sedative hypnotics act on this GABA system. Gamma-aminobutyric acid is the primary inhibitory neurotransmitter system in the CNS. There are GABA receptors with multiple sub-types in different regions, etc. GABA binds to these receptor sites causing a chloride ion channel to open and then all of these inhibitory things take place.
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • The Clinical Toxicology of Gamma-Hydroxybutyrate, Gamma-Butyrolactone and 1,4-Butanediol
    Clinical Toxicology (2012), 50: 458–470 Copyright © 2012 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2012.702218 REVIEW ARTICLE The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol LEO J SCHEP 1 , KAI KNUDSEN 2 , ROBIN J SLAUGHTER 1 , J ALLISTER VALE 3 , and BRUNO MÉGARBANE 4 1 National Poisons Centre, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand 2 Department of Anesthesia and Intensive Care Medicine, Surgical Sciences, Blå Stråket 5, Sahlgrenska University Hospital, Gothenburg, Sweden 3 National Poisons Information Service (Birmingham Unit) and West Midlands Poisons Unit, City Hospital, Birmingham, UK; School of Biosciences and College of Medical and Dental Sciences, University of Birmingham, Birmingham,UK 4 Hôpital Lariboisière, Réanimation Médicale et Toxicologique, INSERM U705, Université Paris-Diderot, Paris, France Introduction. Gamma-hydroxybutyrate (GHB) and its precursors, gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), are drugs of abuse which act primarily as central nervous system (CNS) depressants. In recent years, the rising recreational use of these drugs has led to an increasing burden upon health care providers. Understanding their toxicity is therefore essential for the successful management of intoxicated patients. We review the epidemiology, mechanisms of toxicity, toxicokinetics, clinical features, diagnosis, and management of poisoning due to GHB and its analogs and discuss the features and management of GHB withdrawal. Methods. OVID MEDLINE and ISI Web of Science databases were searched using the terms “ GHB, ” “ gamma-hydroxybutyrate, ” “ gamma-hydroxybutyric acid, ” “ 4-hydroxybutanoic acid, ” “ sodium oxybate, ” “ gamma-butyrolactone, ” “ GBL, ” “ 1,4-butanediol, ” and “ 1,4-BD ” alone and in combination with the keywords “ pharmacokinetics, ” “ kinetics, ” “ poisoning, ” “ poison, ” “ toxicity, ” “ ingestion, ” “ adverse effects, ” “ overdose, ” and “ intoxication.
    [Show full text]
  • Page 498 TITLE 21—FOOD AND
    § 695 TITLE 21—FOOD AND DRUGS Page 498 pealed the permanent appropriation under the title Sec. ‘‘Meat inspection, Bureau of Animal Industry (fiscal 822. Persons required to register. year) (3–114)’’ effective July 1, 1935, provided that such 823. Registration requirements. portions of any Acts as make permanent appropriations 824. Denial, revocation, or suspension of registra- to be expended under such account are amended so as tion. to authorize, in lieu thereof, annual appropriations 825. Labeling and packaging. from the general fund of the Treasury in identical 826. Production quotas for controlled substances. terms and in such amounts as now provided by the laws 827. Records and reports of registrants. providing such permanent appropriations, and author- 828. Order forms. ized, in addition thereto, the appropriation of ‘‘such 829. Prescriptions. other sums as may be necessary in the enforcement of 830. Regulation of listed chemicals and certain the meat inspection laws.’’ In the original, the par- machines. enthetical ‘‘(U.S.C., title 21, secs. 71 to 96, inclusive)’’ 831. Additional requirements relating to online followed the phrase ‘‘meat inspection laws’’. The ‘‘meat pharmacies and telemedicine. inspection laws’’ are classified generally to this chap- ter. PART D—OFFENSES AND PENALTIES Section was not enacted as part of the Federal Meat 841. Prohibited acts A. Inspection Act which is classified to subchapters I to 842. Prohibited acts B. IV–A of this chapter. 843. Prohibited acts C. Section was formerly classified to section 95 of this 844. Penalties for simple possession. title. 844a. Civil penalty for possession of small amounts § 695. Payment of cost of meat-inspection service; of certain controlled substances.
    [Show full text]
  • Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/08/03/jpet.116.234781.DC1 1521-0103/359/1/134–141$25.00 http://dx.doi.org/10.1124/jpet.116.234781 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:134–141, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function s Jahnabi Roy, Reheman Adili, Richard Kulmacz, Michael Holinstat, and Aditi Das Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), University of Michigan Medical School, Ann Arbor, Michigan; and Department of Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, Texas (R.K.) Received April 27, 2016; accepted August 1, 2016 Downloaded from ABSTRACT The inhibition of platelet aggregation is key to preventing particular, the aspirin-DHA anhydride displayed similar effective- conditions such as myocardial infarction and ischemic stroke. ness to aspirin. Platelet aggregation studies conducted in the Aspirin is the most widely used drug to inhibit platelet aggre- presence of various platelet agonists indicated that the aspirin-lipid gation. Aspirin absorption can be improved further to increase conjugates act through inhibition of the cyclooxygenase (COX)– jpet.aspetjournals.org its permeability across biologic membranes via esterification thromboxane synthase (TXAS) pathway.
    [Show full text]
  • Polysubstance Use Disorder
    Driving-Under-the-Influence (DUI) Medication Assisted Treatment (MAT) Polysubstance Integration/Outreach Pilot Project Use Disorder The DUI MAT Integration/Outreach Pilot What is Polysubstance Abuse? Project targets the development and Poly drug use refers to combined drug intoxication to achieve a particular effect. implementation of a recognition and in- In many cases one drug is used as a base, or primary drug, with additional drugs to tervention pilot program for Opioid Use lessen or compensate for the side effects of the primary drug and make the expe- Disorder (OUD) and Polysubstance Use rience more enjoyable with drug synergy effects, or to supplement for the primary Disorder (SUD) to benefit DUI program drug when supply is low. participants. This can include any two substances that create a dependency or negative impact in your life! Examples include alcohol and marijuana, alcohol and prescription DUI MAT services include education, medication, methamphetamine and alcohol. Any two substances used together pre-screens and 2nd level screenings, can result in a Polysubstance use disorder. Although Medication-Assisted Treat- treatment referrals, and counseling sup- ment (MAT) may not be appropriate to treat this issue, there are multiple treatment port. options available. DUI MAT is a voluntary program and will Is the DUI MAT Program Right for You? not impact your DUI program or any le- gal proceedings. DUI MAT is for anyone currently enrolled in a participating DUI Program who may have a substance abuse problem. While the project was developed to address the opioid crisis, you do not need to be exclusively dependent on opioids to participate in the DUI MAT program.
    [Show full text]